Monday, August 24, 2020 10:22:33 AM
https://zeliratx.com/wp-content/uploads/2020/08/ZLD_200819_Sequoia_Initiation_Strong-Buy.pdf
Zelira Therapeutics Ltd (ASX: ZLD, OTCQB: ZLDAF), a global leader in the development of clinically validated cannabinoid medicines, is pleased to announce the initiation of research coverage of the company by Sequoia Financial Group.
Highlights:
Sequoia initiates coverage with STONG BUY recommendation
12 month price target of $0.14
Forecasts based on a conservative estimates of the market potential for HOPE™ (autism) and Zenivol™ (insomnia) only.
Valuations will be revised as additional drugs from the Zelira pipeline are launched into global markets.
Sequoia considers Zelria one of the most exciting stocks in the Australian medicinal cannabis sector.
Recent merger with US-based Ilera Therapeutics seen as a game changer and a key catalyst to accelerate the path to revenues.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM